Antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programme death ligand 1(PD-L1), and programme death 1 (PD-1) have been approved for treatment of metastatic melanoma (1–4). The gene discussed is CTLA4; the disease is metastatic melanoma.